Tromethamine

Summary

Tromethamine (CHEMBL1200391) is an approved small molecule (ATC B05BB03); indicated across 8 conditions including acidosis disorder and malaria.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: B05BB03 (+1 more)
• Indications: 8 conditions
• Clinical trials: 24
• Chemistry: 121.14 Da · C4H11NO3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1200391
Name	Tromethamine
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	6503
ChEBI	CHEBI:9754
ATC	B05BB03, B05XX02
Molecular formula	C4H11NO3
Molecular weight	121.14
InChIKey	LENZDBCJOHFCAS-UHFFFAOYSA-N

SMILES: C(C(CO)(CO)N)O

IUPAC name: 2-amino-2-(hydroxymethyl)propane-1,3-diol

ChEBI definition: A primary amino compound that is tert-butylamine in which one hydrogen attached to each methyl group is replaced by a hydroxy group. A compound widely used as a biological buffer substance in the pH range 7—9; pKa = 8.3 at 20 °C; pKa = 7.82 at 37 °C.

Other ChEBI roles (chemical / environmental): buffer.

Also known as: NSC-6365, Tham, Tris(hydroxymethyl)aminomethane, Tris-base, Trizma, Trometamol, Tromethamine, Tromethamine component of tham-e, SID29215348, TROMETHAMINE, SID29215349, tris buffer

Patent coverage: 277,675 distinct patent families (788,489 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Prelamin-A/C, Menin/Histone-lysine N-methyltransferase MLL.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 2 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
LMNA	6.45	Potency	354.8	nM	CHEMBL_ACT_3643398

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

8 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
acidosis disorder	4	MONDO:0006022	EFO:1000014
malaria	3	MONDO:0005136	EFO:0001068
urinary tract infection	3	MONDO:0100338	EFO:0003103
cataract	3	MONDO:0005129	MONDO:0005129
neoplasm	2	MONDO:0005070	EFO:0000616
cystic fibrosis	1	MONDO:0009061	MONDO:0009061

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 24.

Phase distribution

Phase	Trials
PHASE4	10
Not specified	7
PHASE1	5
PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07176572	PHASE4	NOT_YET_RECRUITING	Analgesic Efficacy of Transcutaneous Electrical Nerve Stimulation and Dexketoprofen in Renal Colic
NCT01558622	PHASE4	UNKNOWN	Intraoperative Use of Dexketoprofen Trometamol, Pethidine Hcl, Tramadol Hcl and Their Combinations for Postoperative Pain Management in Laparoscopic Nissen Fundoplication
NCT02086097	PHASE4	COMPLETED	Dexketoprofen Trometamol in Postoperative Endodontic Pain
NCT02092012	PHASE4	UNKNOWN	Comparison of Preemptive Analgesic Effects of Dexketoprofen Versus Dexmedetomidine on Abdominal Hysterectomy Patients
NCT02160236	PHASE4	UNKNOWN	Comparison of Postoperative Analgesic Efficacy of Intravenous Dexketoprofen Trometamol With Tenoxicam
NCT02380001	PHASE4	COMPLETED	Analgesic Preoperative/Postoperative Dexketoprofen Trometamol in Third Molar Surgery
NCT03107338	PHASE4	COMPLETED	Preventive Treatment of Pain After Dental Implant Surgery
NCT03830398	PHASE4	UNKNOWN	Comparison of Drugs on Headache Treatment After ECT Treatment
NCT04200885	PHASE4	COMPLETED	Is Therapeutic Elastic Bandage As Effective As Corticosteroids Following Third Molar Surgery?
NCT06558916	PHASE4	COMPLETED	Comparison of the Analgesic Efficacy of Dexketoprofen Trometamol, Meperidine, and Paracetamol in Renal Colic
NCT01307020	PHASE2	COMPLETED	Analgesic Effect of Different Combinations of Dexketoprofen Trometamol With Tramadol Hydrochloride in a Model of Moderate to Severe Pain
NCT04161690	PHASE2	UNKNOWN	Evaluation of Dexketoprofen in Total Knee Arthroplasty
NCT00607711	PHASE1	SUSPENDED	Study of Oral Palifosfamide Tris in Solid Tumors
NCT02004548	PHASE1	COMPLETED	Phase I Clinical Study of Metatinib Tromethamine Tablet
NCT02650375	PHASE1	UNKNOWN	Study of Metatinib Tromethamine Tablet
NCT03078088	PHASE1	COMPLETED	Airway Alkalinization and Nasal Colonization
NCT05547438	PHASE1	UNKNOWN	Single Ascending Dose Safety and Tolerability of NTS-104 Healthy Adults
NCT01947205	Not specified	COMPLETED	Pain and Suction Curettage
NCT03420911	Not specified	COMPLETED	Determination of the Effects of Change in Anxiety Level on Pain Perception in Patients Who Present to Emergency Department
NCT03697746	Not specified	UNKNOWN	Comparison of Dexketoprofen, Paracetamol and Ibuprofen in the Treatment of Primary Dysmenorrhea
NCT04213287	Not specified	UNKNOWN	Multimodal Analgesia Methods in Patients Undergoing IPACK Block in Knee Arthroplasty
NCT04252521	Not specified	COMPLETED	Intravenous Metoclopramide Versus Dexketoprofen Trometamol Versus Metoclopramide+ Dexketoprofen Trometamol in Migraine
NCT05125796	Not specified	COMPLETED	Analgesic Use for Pain Relief in Scorpion Sting
NCT07386288	Not specified	COMPLETED	Short-term Perfusion Effects: Dexketoprofen/Tramadol

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).